ライフサイエンスコーパス: indomethacin

1 ric oxide synthase or prostanoid production (indomethacin).

2 nase (LO; baicalein) but not cyclooxygenase (indomethacin).

3 alpha antibody, IL-1-receptor antagonist, or indomethacin.

4 mediate- (10 mg/kg), and low- (5 mg/kg) dose indomethacin.

5 of the mitochondrial pathway of apoptosis by indomethacin.

6 -V241G) in humans that confers resistance to indomethacin.

7 r combined with the cyclooxygenase inhibitor indomethacin.

8 vely inhibiting cyclooxygenase isoforms with indomethacin.

9 wnstream of cyclooxygenase 2 and a target of indomethacin.

10 ation of N-nitro-l-arginine methyl ester and indomethacin.

11 cosa both with and without administration of indomethacin.

12 gregation by SQ29548 (TXA(2) antagonist) and indomethacin.

13 ug ( 26) was about 1.6-fold less potent than indomethacin.

14 attenuated after blocking COX activity with indomethacin.

15 in gastric lesion score compared to that of indomethacin.

16 lon proteins from elimination by sulindac or indomethacin.

17 c symptoms, and is exquisitely responsive to indomethacin.

18 that is deactivated by the administration of indomethacin.

19 observed with the dual COX-1/COX-2 inhibitor indomethacin.

20 ted with the classic anti-inflammatory agent indomethacin.

21 ge and increased susceptibility to injury by indomethacin.

22 inhibitors, aspirin, naproxen, ibuprofen, or indomethacin.

23 ntractions include tocolytic agents, such as indomethacin.

24 or, was evaluated as a control together with indomethacin.

25 ne, but not by the cyclooxygenase inhibitor, indomethacin.

26 bese mice was not affected by treatment with indomethacin.

27 terval [95% CI], 0.23 to 0.53; P<0.001) with indomethacin, 0.15 mmol/L (95% CI, 0.02 to 0.29; P=0.03)

28 kg x 7 days; N = 16), general COX inhibitor (indomethacin; 1 mg/kg x 7 days; N = 16), or no inhibitor

29 l-NAME 10(-4) m) or cyclooxygenase blockade (indomethacin 10(-5) m).

30 dent manner by intraperitoneal injections of indomethacin (10 mg/kg), a nonselective COX-1/COX-2 inhi

31 Nifedipine (10-6 M) and indomethacin (10-5 M) were included in all solutions to

32 n-free after administration of intramuscular indomethacin 100 mg.

33 ments with one time daily 75 mg slow-release indomethacin, 150 mg eplerenone, or 20 mg amiloride adde

34 ly dosed with dexamethasone (0.1 mg/kg/day), indomethacin (2 mg/kg/day), or the specific angiogenesis

35 vivo with clopidogrel (10 mg/kg per day) or indomethacin (2.4 mg/kg per day).

36 Pretreatment with U-73122, indomethacin, 2-aminoethoxydiphenylborane, or verapamil

37 ned in three states: (1) acute PH attack-off indomethacin; (2) pain-free-off indomethacin; and (3) pa

38 ic damage were assessed in rats treated with indomethacin (20 mg/kg) and restraint.

39 nine, 250 microm; l-NNA) and cyclooxygenase (indomethacin, 5 microm; INDO) had no effect on the ampli

40 utamide drug resistance can be surmounted by indomethacin a potent inhibitor of AKR1C3.

41 the resveratrol response was not affected by indomethacin (a cyclooxygenase inhibitor) and sulfaphena

42 by NS 398 (a selective COX-2 inhibitor) and indomethacin (a pan-COX inhibitor).

43 Indomethacin, a common nonsteroidal anti-inflammatory dr

44 Indomethacin, a cyclooxygenase inhibitor, countered the

45 asoconstriction that was sensitive to either indomethacin, a cyclooxygenase inhibitor, or SQ29548, a

46 , and treatment of infected macrophages with indomethacin, a cyclooxygenase-1/cyclooxygenase-2 inhibi

47 nistration of the anti-inflammatory compound indomethacin, a general cyclooxygenase inhibitor, affect

48 e sensitivity of HSA-modified NAA-RFs toward indomethacin, a model drug.

49 Indomethacin, a nonselective cyclooxygenase (COX) inhibi

50 Indomethacin, a nonselective NSAID, caused 2.4-fold more

51 died interactions between the microbiota and indomethacin, a nonsteroidal anti-inflammatory drug (NSA

52 We found that indomethacin, a nonsteroidal anti-inflammatory drug, ind

53 Rectal indomethacin, a nonsteroidal anti-inflammatory drug, is

54 lated glyoxalase 1 (GLO1) as a new target of indomethacin, a widely used antiinflammatory drug.

55 , and inhibition of COX-2 with ibuprofen and indomethacin abrogated STIM1-mediated CRC cell motility.

56 onstrate that sulindac, sulindac sulfone and indomethacin activate the NF-kappaB pathway in colorecta

57 estradiol-17-glucuronide and the xenobiotic indomethacin-acyl-glucuronide are found to exhibit marke

58 In addition, indomethacin administered into the L5-DRG prevented the

59 Concomitantly, indomethacin administration also caused 40-60% increases

60 Indomethacin administration to obese mice did not reduce

61 ups, and IL-6 was quantified with or without indomethacin administration.

62 lished anti-inflammatories dexamethasone and indomethacin, AFC's action was restricted to the site of

63 12, with a few exceptions, patients received indomethacin after their procedure.

64 ar leakage with a cyclo-oxygenase inhibitor (indomethacin), agents that interfere with histamine (pyr

65 Indomethacin also abrogated efficient GTP-dependent late

66 y two cyclooxygenase inhibitors (aspirin and indomethacin) also suggests that prostaglandins may be i

67 A number of indomethacin-amides were found to bind to TCCYP51, inhib

68 f cyclooxygenase-2-selective inhibitors, the indomethacin-amides.

69 Tse et al. now report on the use of indomethacin, an anti-inflammatory drug, to sensitize th

70 trategies were used to generate libraries of indomethacin analogues, which exhibit reduced cyclooxyge

71 n pSTAT6 inhibition by all concentrations of indomethacin and aspirin: between aspirin-sensitive and

72 Nanoliposomes encapsulating indomethacin and decorated with clinically used oxytocin

73 Furthermore, the combination of indomethacin and enzalutamide resulted in significant in

74 y inhibited by the cyclooxygenase inhibitors indomethacin and flurbiprofen.

75 n-steroidal anti-inflammatory drugs, such as indomethacin and ibuprofen, and minocycline, a tetracycl

76 d proliferation response were inhibited with indomethacin and in dominant negative stable transfectio

77 Combined indomethacin and inhibition of endothelial nitric oxide

78 ed in a dose-dependent manner by aspirin and indomethacin and minimally by sodium salicylate.

79 Both indomethacin and morphine were able to block or reverse

80 The addition of PG synthesis inhibitors (indomethacin and NS-398) substantially abrogated LR-MSC-

81 Furthermore, FeTM-4-PyP(5+) synergized with indomethacin and NS397 (1-10 mg/kg) to block both hypera

82 ngs have important clinical implications, as indomethacin and other anti-inflammatory agents are admi

83 dds ratios (ORs) for the association between indomethacin and PEP.

84 ctions in mean pain score were observed with indomethacin and prednisolone in the ED (approximately 1

85 cumulation in caudate putamen 3-5 times, and indomethacin and probenecid increased accumulation in ep

86 nfection overrode the protection provided by indomethacin and restored the increased mortality and mi

87 Indomethacin and SC-236, a selective cyclooxygenase-2 (C

88 drugs (NSAIDs) such as the COX-1/2 inhibitor indomethacin and the COX-2-specific inhibitors NS-398 an

89 urred with a latency of only 1-2 s, and both indomethacin and the cyclooxygenase-1 inhibitor SC-560 b

90 inal autonomic cephalalgias, such as oxygen, indomethacin and triptans, and some part of their therap

91 Indomethacin and verapamil also inhibit the luminal Ca(2

92 Treatment with the COX-inhibitor indomethacin and/or the clinical monoclonal antibody aga

93 e that a subset of NSAIDs such as ibuprofen, indomethacin, and flurbiprofen may have direct Abeta-low

94 , time-dependent COX inhibitors (diclofenac, indomethacin, and flurbiprofen) were unaffected by those

95 al anti-inflammatory drugs (NSAIDs), such as indomethacin, and infection with Helicobacter pylori are

96 mice after co-administration of propranolol, indomethacin, and L-NAME.

97 H attack-off indomethacin; (2) pain-free-off indomethacin; and (3) pain-free after administration of

98 Ibuprofen and indomethacin are nonselective prostaglandin synthetase i

99 ted the ranked order of drug sensitivity for indomethacin, aspirin, MRS-2179 (a P2Y(1) inhibitor), an

100 ctions of low and high doses of ibuprofen or indomethacin at birth (postnatal day [P]1) and on P2 and

101 rted that cyclooxygenase (COX) inhibition by indomethacin augmented allergic airway inflammation in a

102 ntiation in vitro, whereas its inhibition by indomethacin augmented alpha-SMA expression.

103 gh the postnatal period by giving the mother indomethacin before birth.

104 s such as dicoumarol, N-acetylserotonin, and indomethacin blocked sepiapterin reduction, with no effe

105 (1) Indomethacin, but not selective COX-1 or COX-2 inhibitor

106 lective nonsteroidal anti-inflammatory drug, indomethacin, by amidation presents a promising strategy

107 sical assays of model membranes suggest that indomethacin can enhance phase separation and stabilize

108 tios measured through the skin distinguished indomethacin-challenged from same day control rats.

109 antibody partially, but in combination with indomethacin, completely abrogated the protective effect

110 data indicate that Jurkat T cells exposed to indomethacin continue to accumulate fluorescent calcein

111 Amphipathic indomethacin could therefore potentially modulate cell s

112 nding affinity between a set of drugs (i.e., indomethacin, coumarin, sulfadymethoxine, warfarin, and

113 elective (ketorolac tromethamine, ibuprofen, indomethacin), COX-1-selective (SC-560), or COX-2-select

114 The AKR1C3.NADP(+).2'-des-methyl-indomethacin crystal structure was determined, and it re

115 cting SIVH as well as shown that exposure to indomethacin decreases the incidence of SIVH overall.

116 le the best 5-LOX inhibition was attained by indomethacin derivative 17 (IC(5)(0) = 0.9 muM).

117 0.59% of these patients who received rectal indomethacin developed moderate-to-severe PEP vs 4.32% w

118 2.31% of these patients who received rectal indomethacin developed PEP vs 7.53% who did not receive

119 We demonstrate that indomethacin did not inhibit GSIS per se, but activation

120 consecutive patients undergoing ERCP, rectal indomethacin did not prevent post-ERCP pancreatitis.

121 In the presence of L-NAME and indomethacin, dilation to 10(-4) M ATP was significantly

122 Indomethacin diminished the accumulation of microglia/ma

123 re and sugar ratios reflect gut injury in an indomethacin dose dependent manner.

124 Both indomethacin doses suppressed retinal VEGF164 transcript

125 ction and inhibition of COX-2 by NS-398, and indomethacin drastically reduced the levels of PGE(2) an

126 Restoration of of PORH by indomethacin during a HS diet suggests an important role

127 Dexamethasone and indomethacin each reduced pain behavior, synovial inflam

128 Therapeutic levels of indomethacin enhanced phase separation in DPPC/DOPC/Chol

129 Indomethacin enhanced the clustering of H-Ras.GDP and N-

130 e nonselective COX inhibitors salicylate and indomethacin enhanced the expression of iNOS in the rat

131 ment of BHK cells with therapeutic levels of indomethacin enhances cholesterol-dependent nanoclusteri

132 complexes with an enantiomeric pair of these indomethacin ethanolamides were determined at resolution

133 A series of alpha-substituted indomethacin ethanolamides, which exist as R/S-enantiome

134 vity observed with the (S)-alpha-substituted indomethacin ethanolamides.

135 The nonsteroidal anti-inflammatory drug indomethacin exhibits diverse biological effects, many o

136 Deep sequencing analysis showed that indomethacin exposure was associated with alterations in

137 ex vivo administration of either aspirin or indomethacin failed to prevent platelet activation acros

138 atory drugs (such as aspirin, ibuprofen, and indomethacin) failed to influence endotoxin-induced HMGB

139 ly recognized beneficial side effects of the indomethacin family of nonsteroidal antiinflammatory dru

140 hous and recrystallized samples of the drugs indomethacin, felodipine, and acetaminophen.

141 nes recently recommended prophylactic rectal indomethacin for all patients undergoing ERCP, including

142 Ibuprofen may be more effective than indomethacin for suppression of retinal VEGF signaling,

143 Sixteen patients in the indomethacin group (7.2%) and 11 in the placebo group (4

144 titis developed in 13 patients (4.4%) in the indomethacin group and in 27 patients (8.8%) in the plac

145 eveloped in 27 of 295 patients (9.2%) in the indomethacin group and in 52 of 307 patients (16.9%) in

146 During the ED phase, patients in the indomethacin group had more minor adverse events than th

147 ammatory pain) of the formalin test, whereas indomethacin had activity only in phase 2.

148 WT mice treated with indomethacin had greater numbers of total cells, eosinop

149 Indomethacin had no effect on adipose tissue mass, gluco

150 Dexamethasone reduced, but indomethacin had no significant effect on, the total joi

151 Oral prednisolone and indomethacin had similar analgesic effectiveness among p

152 Stable glasses of indomethacin (IMC) were prepared by using physical vapor

153 For indomethacin (IMC), an organic glass able to grow surfac

154 mRNA expression after exposure to MK886 and indomethacin in a time-dependent fashion.

155 beta-catenin is partially driving effects of Indomethacin in cisplatin-resistant cells.

156 ate the efficacy of rectal administration of indomethacin in reducing the incidence of post-ERCP panc

157 as potent inhibitors such as diclofenac and indomethacin in the same experimental conditions).

158 Inhibition of PGE2 synthesis by indomethacin in vitro, targeted deletion of EP2 in prima

159 n of PGE2 reversed the beneficial effects of indomethacin in vitro.

160 by coinjection of the anti-inflammatory drug indomethacin in wild-type but not TKO brains.

161 By contrast, indomethacin increased proliferation in the SGZ and late

162 acrophages with the cyclooxygenase inhibitor indomethacin increases TNFalpha production to the level

163 Administration of indomethacin (IND) leads to the formation of lipid rafts

164 t of the nonsteroidal anti-inflammatory drug indomethacin (IND) on MDSCs, depending on whether they w

165 armacologically reduced by administration of indomethacin (INDO; 1.2 mg kg(-1)) or unaltered (placebo

166 Neither blockade of cyclooxygenase with indomethacin (Indo; 5 microm) nor blockade of endothelia

167 t or a regular diet supplemented or not with indomethacin (+/-INDO) for 7 weeks.

168 rvivin confer protection against ethanol and indomethacin induced injury.

169 Indomethacin-induced acute ileitis led to repression of

170 SEGA (3a) inhibits indomethacin-induced down-regulation of bcl-2 and up-reg

171 with H. pylori also stimulated formation of indomethacin-induced gastric lesions and mucosal cell de

172 ent mice are sensitive to the development of indomethacin-induced gastric lesions and mucosal cell de

173 Indomethacin-induced ileal injury was greater in the c-f

174 seline morphology or morphometry but reduced indomethacin-induced injury in overexpressing hPSTI regi

175 This indomethacin-induced injury was associated with activati

176 ed MOS, as is evident from the inhibition of indomethacin-induced mitochondrial protein carbonyl form

177 GI2 receptor (IP) signaling was critical for indomethacin-induced, STAT6-independent proallergic effe

178 applications in EOC and found that (i) NSAID Indomethacin induces robust cell death in primary patien

179 tically examined whether amphiphiles such as indomethacin influence Ras protein nanoclustering in int

180 Ninety minutes after indomethacin ingestion, cerebral blood flow velocity (CB

181 , but activation of GPR40 in the presence of indomethacin inhibited glucose-dependent insulin secreti

182 In this mouse model, both dexamethasone and indomethacin inhibited TPA-induced edema and MPO activit

183 M-1 cell integrity at baseline and following indomethacin injury.

184 n of the TLS found in ultrastable glasses of indomethacin is argued to be due to their particular ani

185 tial G1/S arrest, the G1/S arrest induced by indomethacin is, at least in part, caused by the inhibit

186 The slow, tight-binding inhibitor, indomethacin, is a potent inhibitor of 2-AG and AA oxyge

187 nonsteroidal anti-inflammatory drug (NSAID), indomethacin, is reported.

188 potencies of aspirin, celecoxib, diclofenac, indomethacin, lumiracoxib, meloxicam, naproxen, rofecoxi

189 and salicylate, but not aspirin, celecoxib, indomethacin, lumiracoxib, meloxicam, or SC560, against

190 anti-inflammatory drugs, tolfenamic acid and indomethacin, markedly reduce direct cell-to-cell spread

191 Prophylactic indomethacin may decrease Severe Intraventricular Hemorr

192 SEGA (3a) corrects indomethacin-mediated mitochondrial dysfunction in vivo

193 SEGA (3a) in vivo blocks indomethacin-mediated MOS, as is evident from the inhibi

194 y COX product(s) responsible for restraining indomethacin-mediated STAT6-independent allergic inflamm

195 tion of l-NAME with cyclooxygenase inhibitor indomethacin mimicked the effect of denudation.

196 given either a single 100-mg dose of rectal indomethacin (n = 223) or a placebo suppository (n = 226

197 One HS diet group subset received 100 mg of indomethacin (non-selective COX-1 and COX-2 inhibitor),

198 We examined: (1) the effects of indomethacin (nonselective NSAID), celecoxib and NS-398

199 ry in rat gastric mucosa; (2) the effects of indomethacin, NS-398, SC-560, and SC-560 plus NS-398 on

200 SEGA (3a) prevents indomethacin (NSAID)-induced mitochondrial oxidative str

201 The effect of indomethacin on AM phagocytosis could be mimicked by an

202 intolerance was monitored, and the effect of indomethacin on glucose-stimulated insulin secretion (GS

203 Here we examined the effect of indomethacin on membrane lateral heterogeneity.

204 the effects of early postnatal ibuprofen and indomethacin on ocular and systemic VEGF, IGF-I, and GH

205 heets similarly showed a selective effect of indomethacin on promoting cholesterol-dependent, but not

206 iciency diminished the stimulatory effect of indomethacin on STAT6-independent IL-5 and IL-13 respons

207 re further used to follow crystallization of indomethacin on tablet surfaces under two storage condit

208 Inhibition of cyclooxygenase by indomethacin only slightly reduced the vasodilatory resp

209 For glasses prepared from indomethacin or 1,3-bis-(1-naphthyl)-5-(2-naphthyl)benze

210 is were assigned to receive 100 mg of rectal indomethacin or a 2.6 g suppository of glycerin immediat

211 if exposure of pregnant rats to analgesics (indomethacin or acetaminophen) affected GC development a

212 by EPCs were inhibited by the COX inhibitor indomethacin or by genetic inactivation of COX-1 or PGI(

213 ndin E2-dependent phase, which is blocked by indomethacin or by null mutation of the EP3 prostanoid r

214 itivity was not altered by pretreatment with indomethacin or capsazepine, a selective antagonist of t

215 Systemic administration of indomethacin or celecoxib (cyclo-oxygenase inhibitors),

216 d by inhibition of cyclooxygenase-2 (COX-2) (indomethacin or celecoxib) or of TXA2/prostaglandin H2 r

217 2 was seen throughout the gut in response to indomethacin or dextran sodium sulfate treatment.

218 By contrast, the inhibitory effects of indomethacin or diclofenac, which also inhibit both cycl

219 creatitis to receive a single dose of rectal indomethacin or placebo immediately after ERCP.

220 domly assigned (1:1 ratio) to receive either indomethacin or prednisolone.

221 combined inhibition of COX-1 and COX-2 with indomethacin or selective inhibition of COX-2 with Merck

222 Inhibition of 15-PGDH using either indomethacin or SW033291 significantly reduced the furth

223 and treated the mice with the COX inhibitor indomethacin or vehicle for analyses of the primary and

224 The COX inhibitor indomethacin or vehicle was administered in drinking wat

225 (GLP-1) was functionalized with diflunisal, indomethacin, or both.

226 Blocking PGE2 synthesis with indomethacin overcame the phagocytic and killing defects

227 oped PEP vs 7.53% who did not receive rectal indomethacin (P < .001) and 0.59% of these patients who

228 vere PEP vs 4.32% who did not receive rectal indomethacin (P = .001).

229 Indomethacin partially blocked and did not reverse paw e

230 ice treated subcutaneously with slow-release indomethacin pellets, suggesting a role for prostanoids,

231 l microbiome by antibiotic treatment altered indomethacin pharmacokinetics and pharmacodynamics, whic

232 We found that supplementation with indomethacin prevented HF/HS-induced obesity and diet-in

233 re potent AI agent than aspirin, whereas the indomethacin prodrug ( 26) was about 1.6-fold less poten

234 d that the aspirin prodrug 23 (UI = 0.7) and indomethacin prodrug 26 (UI = 0) were substantially less

235 patients with malignant obstruction, rectal indomethacin provided the greatest benefit to patients w

236 NS-398 and indomethacin reduced inflammation and bone growth.

237 Importantly, in vivo treatment with indomethacin reduced PGE2 levels in lung homogenates and

238 Indomethacin reduced PKA and Akt activation by approxima

239 Rectal indomethacin reduced the incidence of post-ERCP pancreat

240 ibition of prostaglandin (PG) synthesis with indomethacin reduced the magnitude of the changes in 20:

241 Rectal indomethacin reduced the odds of PEP by 65% (OR, 0.35; 9

242 patients with malignant obstruction, rectal indomethacin reduced the risk of PEP by 64% (OR, 0.36; 9

243 MK886 but not the cyclooxygenase inhibitor, indomethacin, reduced growth, increased apoptosis, and u

244 Treatment with the cyclooxygenase inhibitor indomethacin reduces beta-catenin levels and leads to a

245 mice with the cyclooxygenase (COX) inhibitor indomethacin reduces the infectious burden, proinflammat

246 Rectal indomethacin reduces the risk of pancreatitis after endo

247 r inhibition of AKR1C3 enzymatic activity by indomethacin resensitized enzalutamide-resistant prostat

248 ayed larger clots and another presented with indomethacin resistance (revealing a novel heterozygote

249 egrin and Cox-2 activation by echistatin and indomethacin, respectively, each blocked the fluid shear

250 Indomethacin restored microcirculatory blood flow and re

251 Inhibition of the COX pathway with indomethacin resulted in delayed worm expulsion in selen

252 inistration of a nonselective COX inhibitor (indomethacin), selective COX-1 (valeryl salicylate), or

253 l cycle analysis of HT-29 cells exposed with indomethacin showed a partial G1/S arrest and slow DNA s

254 Contrary to our expectations, indomethacin significantly decreased both the initial re

255 Indomethacin significantly reduced eGFR and plasma renin

256 high risk for post-ERCP pancreatitis, rectal indomethacin significantly reduced the incidence of the

257 At the CP, verapamil and probenecid (but not indomethacin) significantly increased 125I-T4 accumulati

258 nd E268A mutants had functional responses to indomethacin similar to the wild-type receptor.

259 y because of gastrointestinal intolerance to indomethacin (six patients) and hypotension with epleren

260 We found that indomethacin strongly reduced the basal level of extrace

261 ation was inhibited by acetaminophen but not indomethacin, suggesting catalysis occurred by the perox

262 plication of the model to patients receiving indomethacin suggests a benefit at the highest risk leve

263 rs) derivatized with clinically used NSAIDs (indomethacin, sulindac, ketoprofen, ibuprofen, diclofena

264 ing nitric oxide (l-NAME) and prostaglandin (indomethacin) synthesis increased CGRP EC50 in both age

265 -heat measurements of ultrastable glasses of indomethacin that clearly show the disappearance of the

266 s and during interictal pain-free states off indomethacin that is deactivated by the administration o

267 ntiinflammatory drugs (NSAIDs) ibuprofen and indomethacin, the drugs widely used as pain relievers in

268 Three different solid-state forms of indomethacin-the crystalline gamma and alpha forms, as w

269 fteen patients became normokalemic: six with indomethacin, three with eplerenone, and six with amilor

270 s in their microbiota and their responses to indomethacin - thus, the drug-microbe interactions descr

271 -type, and c-fos-null mice were treated with indomethacin to assess the response to acute inflammatio

272 xposed CD-1 mice were topically treated with indomethacin to block endogenous PGE(2) production, and

273 Our results showed that administration of indomethacin to PiZ mice resulted in increased hepatic i

274 We investigated the potential of rectal indomethacin to prevent post-ERCP pancreatitis (PEP) in

275 We used oral indomethacin to reduce the cerebrovascular reactivity to

276 omide, vitamin A cogeners, or retinoids; and indomethacin tocolysis.

277 olymerized alpha(1)-ATZ protein in livers of indomethacin-treated PiZ mice compared to vehicle-treate

278 was observed only in selenium-deficient and indomethacin-treated selenium-supplemented mice but not

279 fection compared to monomicrobial infection; indomethacin treatment also decreased elevated PGE2 leve

280 Indomethacin treatment dose-dependently reduced survivin

281 Indomethacin treatment partially restored T cell prolife

282 Inhibition of PGE(2) production with indomethacin treatment resulted in increased numbers of

283 Neither indomethacin treatment to block PG synthesis nor anti-CD

284 than the parent drugs aspirin (UI = 51) and indomethacin (UI = 64).

285 ophen, and other NSAID (ibuprofen, naproxen, indomethacin) use were based on a self-administered ques

286 Indomethacin, used to inhibit cyclooxygenase, also inhib

287 s with malignant biliary obstruction, rectal indomethacin was associated with a significant decrease

288 the anti-inflammatory (AI) drugs aspirin and indomethacin was covalently linked to the 1-(2-carboxypy

289 Indomethacin was tested in both acute and chronic exposu

290 Indomethacin was the most effective but can cause gastro

291 Indomethacin was used as a model active pharmaceutical i

292 n, acetaminophen (paracetamol), sulindac and indomethacin, was also achieved in supramolecular gel me

293 By blocking PGE2 production with indomethacin, we made a striking finding that endogenous

294 further evaluate the biophysical effects of indomethacin, we measured fluorescence polarization of t

295 Electrolyte supplements and indomethacin were used frequently to induce catch-up gro

296 nd after the ex vivo addition of aspirin and indomethacin) were analyzed in 700 consecutive aspirin-t

297 In contrast, indomethacin, which inhibited PGE(2) production, partial

298 ant (a neurokinin 1 receptor antagonist), or indomethacin with pyrilamine significantly reduced vascu

299 2 and COX2 using amino-guanidine and aspirin/indomethacin yielded an additive reduction in the growth

300 difications on the 3-acetic acid part of the indomethacin yielding an amide-nitrate derivative 32 and